ホーム / ニュース / 会社のニュース

Why Are We the Best Choice?

Jan. 20, 2021

There are currently more than 200 new crown candidate vaccine projects under development, of which 63 have entered clinical trials, 11 candidate vaccine projects have entered Phase III large-scale clinical trials, and three candidate vaccine projects are from China. With the successful overseas phase III trials of the new crown vaccine, there were no serious adverse reactions in 60,000 subjects in China, and safety and protection data were obtained for Phase III trials. November 25, Sinopharm has submitted a listing application to the State Food and Drug Administration. In this environment, vaccine cold chain temperature-controlled transport, has become the focus of attention. How to better achieve the full chain of vaccine circulation safe, stable, efficient operation has attracted much attention!

COVID-19 Vaccine Container Supplier

COVID-19 Vaccine Container Supplier

We are the only pharmaceutical logistics company in China that has participated in the whole process of drafting the standards of temperature control logistics service specification for in vitro diagnostic reagents and the national standards of human biological sample management specification and drug cold chain logistics operation specification.

The company has many years of customer service, Foreign Enterprises, has accumulated a large number of cold chain logistics operation experience, and has a strong emergency support system.

We are the world's only phase change materials, refrigerated containers, cold chain hardware and software integration of research and production, with 55 patents (including 6 patents) , 12 professional certification at home and abroad, r & D, Production and service capacity leading in China

In 2020, CIMC COLD CLOUD was honored as the third of the top 20 enterprises in the cold chain of medicine in 2020. It is the leader of the domestic enterprises in the cold chain of medicine.

There are currently more than 200 new crown candidate vaccine projects under development, of which 63 have entered clinical trials, 11 candidate vaccine projects have entered Phase III large-scale clinical trials, and three candidate vaccine projects are from China. With the successful overseas phase III trials of the new crown vaccine, there were no serious adverse reactions in 60,000 subjects in China, and safety and protection data were obtained for Phase III trials. November 25, Sinopharm has submitted a listing application to the State Food and Drug Administration. In this environment, vaccine cold chain temperature-controlled transport, has become the focus of attention. How to better achieve the full chain of vaccine circulation safe, stable, efficient operation has attracted much attention!

Our company is COVID-19 Vaccine Container Supplier, welcome to consult us.


最新の投稿
人気製品
COVID-19ワクチン容器 COVID-19ワクチン容器
EPE断熱コンテナー EPE断熱コンテナー
LY-RTH1000B温度レコーダー LY-RTH1000B温度レコーダー
+8618731666682 +8618731666682 290730855 +8618731666682

+8618731666682